Lumosa Therapeutics Co., Ltd. (TPEX:6535)
Taiwan
· Delayed Price · Currency is TWD 154.50
+3.00 (1.98%)
Mar 10, 2026, 10:59 AM CST
Lumosa Therapeutics Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -340.54 | -424.78 | -238.04 | -494.66 | 95.95 | Upgrade
|
| Depreciation & Amortization | 11.26 | 8.3 | 23.1 | 21.92 | 32.02 | Upgrade
|
| Other Amortization | - | 0.12 | 0.26 | 0.25 | 0.08 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 10.37 | - | 102.52 | Upgrade
|
| Loss (Gain) From Sale of Investments | 40.29 | 102.24 | -119.08 | 217.4 | -627.61 | Upgrade
|
| Stock-Based Compensation | -4.89 | 37.96 | 8.59 | 5.03 | 3.22 | Upgrade
|
| Provision & Write-off of Bad Debts | -0.01 | 0.18 | 0.15 | - | - | Upgrade
|
| Other Operating Activities | -3.21 | -18.45 | -19.75 | -9.18 | 0.1 | Upgrade
|
| Change in Accounts Receivable | 7.74 | -8.81 | 1.84 | -4.31 | 7.93 | Upgrade
|
| Change in Inventory | -1 | 6.13 | 4.77 | -26.3 | -50.61 | Upgrade
|
| Change in Accounts Payable | -0.11 | -0.07 | 0.5 | -13.51 | 14.47 | Upgrade
|
| Change in Unearned Revenue | -0.24 | - | -3.85 | 2.2 | -0.32 | Upgrade
|
| Change in Other Net Operating Assets | -69.78 | 0.86 | 2.91 | 0.7 | -30.35 | Upgrade
|
| Operating Cash Flow | -360.5 | -296.33 | -328.21 | -300.46 | -452.6 | Upgrade
|
| Capital Expenditures | -0.67 | -0.45 | -14.32 | -2.29 | -0.09 | Upgrade
|
| Sale (Purchase) of Intangibles | - | - | -0.7 | - | -0.49 | Upgrade
|
| Investment in Securities | 366.77 | -790.65 | 247.6 | -66.92 | -36.41 | Upgrade
|
| Other Investing Activities | 4.09 | 4 | 8 | - | - | Upgrade
|
| Investing Cash Flow | 370.19 | -787.1 | 240.58 | -69.2 | -36.98 | Upgrade
|
| Long-Term Debt Repaid | -6.79 | -4.13 | -4.33 | -4.65 | -5.47 | Upgrade
|
| Net Debt Issued (Repaid) | -6.79 | -4.13 | -4.33 | -4.65 | -5.47 | Upgrade
|
| Issuance of Common Stock | - | 897.75 | 0.29 | 0.81 | 436.74 | Upgrade
|
| Repurchase of Common Stock | -56.8 | - | - | - | - | Upgrade
|
| Other Financing Activities | - | - | 0.1 | 50 | - | Upgrade
|
| Financing Cash Flow | -63.59 | 893.62 | -3.95 | 46.17 | 431.28 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0 | 0.05 | -0.03 | 0.02 | -0.01 | Upgrade
|
| Net Cash Flow | -53.89 | -189.76 | -91.6 | -323.47 | -58.32 | Upgrade
|
| Free Cash Flow | -361.16 | -296.78 | -342.53 | -302.74 | -452.69 | Upgrade
|
| Free Cash Flow Margin | -1007.96% | -757.97% | -601.82% | -1136.33% | -2607.34% | Upgrade
|
| Free Cash Flow Per Share | -2.17 | -1.81 | -2.11 | -1.86 | -3.00 | Upgrade
|
| Cash Interest Paid | 0.2 | 0.19 | 0.05 | 0.15 | 0.26 | Upgrade
|
| Cash Income Tax Paid | -6.72 | 0.39 | 0.57 | -0.61 | 0.06 | Upgrade
|
| Levered Free Cash Flow | -259.25 | -180.01 | -212.08 | -207.14 | -293.1 | Upgrade
|
| Unlevered Free Cash Flow | -259.13 | -179.9 | -212.05 | -207.05 | -292.94 | Upgrade
|
| Change in Working Capital | -63.39 | -1.88 | 6.18 | -41.21 | -58.89 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.